Suppr超能文献

病因治愈可预防肝硬化腹水首次单一失代偿事件患者进一步恶化和死亡。

Etiological cure prevents further decompensation and mortality in patients with cirrhosis with ascites as the single first decompensating event.

机构信息

Unit of Internal Medicine and Hepatology, Department of Medicine, University of Padova, Padova, Italy.

Department of Internal Medicine III, Division of Gastroenterology and Hepatology, Medical University of Vienna, Vienna, Austria.

出版信息

Hepatology. 2023 Oct 1;78(4):1149-1158. doi: 10.1097/HEP.0000000000000460. Epub 2023 May 17.

Abstract

BACKGROUND AND AIMS

Removal/suppression of the primary etiological factor reduces the risk of decompensation and mortality in compensated cirrhosis. However, in decompensated cirrhosis, the impact of etiologic treatment is less predictable. We aimed to evaluate the impact of etiological treatment in patients with cirrhosis who developed ascites as single index decompensating event.

APPROACH AND RESULTS

Patients with cirrhosis and ascites as single first decompensation event were included and followed until death, liver transplantation, or Q3/2021. The etiology was considered "cured" (alcohol abstinence, hepatitis C cure, and hepatitis B suppression) versus "controlled" (partial removal of etiologic factors) versus "uncontrolled." A total of 622 patients were included in the study. Etiology was "cured" in 146 patients (24%), "controlled" in 170 (27%), and "uncontrolled" in 306 (49%). During follow-up, 350 patients (56%) developed further decompensation. In multivariable analysis (adjusted for age, sex, varices, etiology, Child-Pugh class, creatinine, sodium, and era of decompensation), etiological cure was independently associated with a lower risk of further decompensation (HR: 0.46; p = 0.001). During follow-up, 250 patients (40.2%) died, while 104 (16.7%) underwent LT. In multivariable analysis, etiological cure was independently associated with a lower mortality risk (HR: 0.35, p < 0.001).

CONCLUSIONS

In patients with cirrhosis and ascites as single first decompensating event, the cure of liver disease etiology represents a main treatment goal since this translates into considerably lower risks of further decompensation and mortality.

摘要

背景与目的

在代偿期肝硬化中,去除/抑制原发性病因可降低失代偿和死亡风险。然而,在失代偿期肝硬化中,病因治疗的影响较难预测。我们旨在评估病因治疗对发生腹水这一单一失代偿事件的肝硬化患者的影响。

方法和结果

纳入了以腹水为首次单一失代偿事件的肝硬化患者,并对其进行随访,直至死亡、肝移植或 2021 年 9 月。病因被认为是“治愈”(戒酒、丙型肝炎治愈和乙型肝炎抑制)、“控制”(部分去除病因)还是“未控制”。共纳入 622 例患者。146 例(24%)患者的病因被“治愈”,170 例(27%)患者的病因被“控制”,306 例(49%)患者的病因未被“控制”。在随访期间,350 例患者(56%)发生进一步的失代偿。多变量分析(调整年龄、性别、静脉曲张、病因、Child-Pugh 分级、肌酐、钠和失代偿时代)表明,病因治愈与进一步失代偿的风险降低独立相关(HR:0.46;p = 0.001)。在随访期间,250 例患者(40.2%)死亡,104 例患者(16.7%)接受了肝移植。多变量分析表明,病因治愈与死亡率降低独立相关(HR:0.35,p < 0.001)。

结论

在以腹水为首次单一失代偿事件的肝硬化患者中,治愈肝脏疾病病因是主要的治疗目标,因为这可显著降低进一步失代偿和死亡的风险。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验